Expertise in
2
conditions

Diogo A. Bastos

Sao Paulo, SP, BR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Sao Paulo, SP, BR 
OverviewLocationsClinical Research

Overview

Diogo Bastos practices in Sao Paulo, Brazil. Mr. Bastos is highly rated in 2 conditions, according to our data. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Prostatectomy, and Orchiectomy.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Sao Paulo, SP, Brazil
Other Locations
Brasilia, DF, Brazil
Echapora, SP 01308050, Brazil
Porto Alegre, RS, Brazil

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Other
Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Sequential Treatment With Docetaxel and Enzalutamide
Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Sequential Treatment With Docetaxel and Enzalutamide
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: Docetaxel, Enzalutamide
Study Phase: Phase 2
Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Testosterone Cypionate, Darolutamide
Study Phase: Phase 2
Phase II Study of Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for Patients With High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy
Phase II Study of Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for Patients With High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Drug
Study Drugs: Goserelin, Prednisone, Abiraterone, Apalutamide
Study Phase: Phase 2
Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Bipolar Androgen Therapy (BAT)
Prospective Biomarker Analysis of Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Undergoing Bipolar Androgen Therapy (BAT)
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Drug
Study Drug: Testosterone cypionate
Study Phase: Phase 2
Multicenter Database of Patients With Germ Cell Tumor in Order to Characterize Clinicopathologically and to Evaluate Cancer Treatment Outcomes
Multicenter Database of Patients With Germ Cell Tumor in Order to Characterize Clinicopathologically and to Evaluate Cancer Treatment Outcomes
Enrollment Status: Completed
Publish Date: December 27, 2021
Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
Enrollment Status: Unknown
Publish Date: August 26, 2021
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
Biomarker Study of Patients With Metastatic Clear Cell Renal Carcinoma (ccRCC) Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib
Biomarker Study of Patients With Metastatic Clear Cell Renal Carcinoma (ccRCC) Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib
Enrollment Status: Unknown
Publish Date: September 04, 2019
Intervention Type: Drug
Study Drug: Sunitinib
Study Phase: Phase 2
View 7 Less Clinical Trials

70 Total Publications

177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bastos's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile